The coordinated P53 and estrogen receptor Cis-regulation at an FLT1 Promoter SNP is specific to genotoxic stress and estrogenic compound

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Ciribilli, Yari ^a   Andreotti, Virginia ^a   Menendez, Daniel ^b   Langen, Jan Stephan ^c   Schoenfelder, Gilbert ^c,d   Resnick, Michael A ^b   Inga, Alberto ^a,e  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF TRENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; DOXORUBICIN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; MESSENGER RNA; PROTEIN P53; PROTEIN P63; PROTEIN P73; VASCULOTROPIN RECEPTOR 1; ESTROGEN; FLT1 PROTEIN, HUMAN;

ARTICLE; CELL STRAIN HCT116; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; GENE LOCATION; GENOME SIZE; GENOTOXICITY; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; TRANSCRIPTION REGULATION; DNA DAMAGE; DRUG EFFECT; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; ENHANCER ELEMENTS, GENETIC; ESTROGENS; FLUOROURACIL; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77956320240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010236     Document Type: Article

References (68)

1. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
2. Autiero M, Waltenberger J, Communi D, Kranz A, Moons, L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943.
3. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956.
4. Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272: 23659- 23667.
5. Luttun A, Tjwa M, Carmeliet P (2002) Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 979: 80-93.
6. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
7. Andre T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, et al. (2000) Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 86: 174-181.
8. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, et al. (2005) A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxiainducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65: 7267-7275.
9. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, et al. (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24: 2647-2653.
10. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, et al. (2003) Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56: 107-113.
11. Ilhan N, Deveci F (2004) Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 37: 840-845.
12. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, et al. (2007) Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4: e186.
13. Heidenreich R, Machein M, Nicolaus A, Hilbig A, Wild C, et al. (2004) Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int J Cancer 111: 348-357.
14. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, et al. (2006) Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12: 5841-5849.
15. An P, Lei H, Zhang J, Song S, He L, et al. (2004) Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 111: 165-173.
16. Kaplan RN, Riba RR, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initialte the premetastatic niche. Nature 438: 820-827.
17. Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, et al. (2007) A singlenucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol 27: 2590-2600.
18. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, et al. (2006) A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA 103: 1406-1411.
19. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
20. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207- 219.
21. Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW (1994) p53 tagged sites from human genomic DNA. Hum Mol Genet 3: 1537- 1542.
22. Veprintsev DB, Fersht AR (2008) Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 36: 1589-1598.
23. Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P (1995) Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol 15: 2157-2165.
24. McLure KG, Lee PW (1998) How p53 binds DNA as a tetramer. Embo J 17: 3342-3350.
25. Inga A, Storici F, Darden TA, Resnick MA (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22: 8612-8625.
26. Jordan JJ, Menendez D, Inga A, Nourredine M, Bell D, et al. (2008) Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 4: e1000104.
27. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737.
28. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116: 561-570.
29. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869-36872.
30. Hall JM, Korach KS (2002) Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens. J Biol Chem 277: 44455-44461.
31. Hall JM, McDonnell DP, Korach KS (2002) Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16: 469-486.
32. Driscoll MD, Sathya G, Muyan M, Klinge CM, Hilf R, et al. (1998) Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 273: 29321-29330.
33. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato, AC (1988) A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res 16: 647-663.
34. Porter W, Saville B, Hoivik D, Safe S (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11: 1569-1580.
35. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
36. Gewirth DT, Sigler PB (1995) The basis for half-site specificity explored through a non-cognate steroid receptor-DNA complex. Nat Struct Biol 2: 386-394.
37. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, et al. (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113: 1661-1670.
38. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
39. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, et al. (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830.
40. Sun XX, Dai MS, Lu H (2007) 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 282: 8052-8059.
41. Ju J, Schmitz JC, Song B, Kudo K, Chu E (2007) Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 13: 4245-4251.
42. Kaeser MD, Iggo RD (2004) Promoter-specific p53-dependent histone acetylation following DNA damage. Oncogene 23: 4007-4013.
43. Espinosa JM, Verdun RE, Emerson BM (2003) p53 functions through stressand promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12: 1015-1027.
44. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, et al. (2004) Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109: 533-540.
45. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, et al. (2005) 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res 11: 1722- 1732.
46. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, et al. (2002) 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62: 3691-3697.
47. Kaeser MD, Pebernard S, Iggo RD (2004) Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 279: 7598-7605.
48. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
49. Espinosa JM (2008) Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27: 4013-4023.
50. Perez CA, Ott J, Mays DJ, Pietenpol JA (2007) p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 26: 7363-7370.
51. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, et al. (2005) Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 25: 6077-6089.
52. Jegga AG, Inga A, Menendez D, Aronow BJ, Resnick MA (2008) Functional evolution of the p53 regulatory network through its target response elements. Proc Natl Acad Sci USA 105: 944-949.
53. Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, et al. (2005) MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell 19: 89-100.
54. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
55. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23: 7350-7360.
56. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
57. Pal S, Datta K, Mukhopadhyay D (2001) Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61: 6952-6957.
58. Bian J, Sun Y (1997) Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17: 6330-6338.
59. Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, et al. (2007) Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem 282: 5661-9.
60. Kunz C, Pebler S, Otte J, von der Ahe D (1995) Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 23: 3710-7.
61. Teodoro JG, Parker AE, Zhu X, Green MR (2006) p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313: 968-971.
62. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, et al. (2005) p53 is a suppressor of inflammatory response in mice. Faseb J 19: 1030-1032.
63. Roger L, Gadea G, Roux P (2006) Control of cell migration: a tumour suppressor function for p53? Biol Cell 98: 141-152.
64. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183- 90.
65. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
66. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
67. Chappel JC, Taylor SM, Ferrara N, Bautch VL (2009) Local Guidance of Emerging Vessel Sprouts Requires Soluble Flt-1. Developmental Cell 17: 377-386.
68. Menendez D, Inga A, Resnick MA (2006) The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 26: 2297-2308.